Skip to the page

Data / Drug companies / Rabeprazole sodium

Rabeprazole sodium: 20 companies and 37 products in the FDA NDC directory

Rabeprazole sodium is listed in the FDA National Drug Code Directory by 20 companies, with 37 products in commercial distribution. 36 of the products (97.3%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet, delayed release, and the newest product started marketing on December 8, 2025.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Companies listing it
20
Products
37
Generic (ANDA) products
36 (97.3%)
Application numbers
6
Routes
Oral
Brand names
Aciphex
openFDA record search
api.fda.gov

Companies that list rabeprazole sodium

Ranked by number of products. Finished drugs in commercial distribution.

CompanyProductsMain dosage formsMain marketing categoryNewest product started
Advanced Rx of Tennessee, LLC4tablet, delayed releaseGeneric drugs (ANDA)November 15, 2024
Bryant Ranch Prepack4tablet, delayed releaseGeneric drugs (ANDA)April 27, 2018
Asclemed USA, Inc.3tablet, delayed releaseGeneric drugs (ANDA)April 27, 2018
Preferred Pharmaceuticals Inc.3tablet, delayed releaseGeneric drugs (ANDA)December 8, 2025
A-S Medication Solutions2tablet, delayed releaseGeneric drugs (ANDA)April 27, 2018
Bryant Ranch Prepack2tablet, delayed releaseGeneric drugs (ANDA)April 27, 2018
Direct_Rx2tablet, delayed releaseGeneric drugs (ANDA)January 14, 2021
Proficient Rx LP2tablet, delayed releaseGeneric drugs (ANDA)November 8, 2013
Proficient Rx LP2tablet, delayed releaseGeneric drugs (ANDA)April 27, 2018
Remedyrepack Inc.2tablet, delayed releaseGeneric drugs (ANDA)September 1, 2021
St. Mary's Medical Park Pharmacy2tablet, delayed releaseGeneric drugs (ANDA)May 6, 2021
Advagen Pharma Ltd1tablet, delayed releaseGeneric drugs (ANDA)June 1, 2017
Ascend Laboratories, LLC1tablet, delayed releaseGeneric drugs (ANDA)April 27, 2018
Aurobindo Pharma Limited1tablet, delayed releaseGeneric drugs (ANDA)February 17, 2017
Chartwell RX, LLC1tablet, delayed releaseGeneric drugs (ANDA)November 8, 2013
Golden State Medical Supply, Inc.1tablet, delayed releaseGeneric drugs (ANDA)November 8, 2013
Lannett Company, Inc.1tablet, delayed releaseGeneric drugs (ANDA)November 8, 2013
Phoenix RX LLC1tablet, delayed releaseGeneric drugs (ANDA)April 27, 2018
Torrent Pharmaceuticals Limited1tablet, delayed releaseGeneric drugs (ANDA)November 8, 2013
Waylis Therapeutics LLC1tablet, delayed releaseNew drug applications (NDA)May 15, 2022

Dosage forms

Dosage formProductsShare
Tablet, delayed release37100%

Marketing categories

Marketing categoryProductsShare
Generic drugs (ANDA)3697.3%
New drug applications (NDA)12.7%

Pharmacologic classes

ClassProducts
Proton Pump Inhibitor37

Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.